{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T08:58:05Z","timestamp":1782377885046,"version":"3.54.5"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006492","name":"National Institute of Allergy and Infectious Diseases Division of Intramural Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.vaccine.2026.128358","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T05:00:32Z","timestamp":1771995632000},"page":"128358","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["The safety, reactogenicity, and immunogenicity of the self-amplifying mRNA COVID-19 vaccine GRT-R910 as a booster in healthy adults"],"prefix":"10.1016","volume":"77","author":[{"given":"Jennifer A.","family":"Whitaker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina A.","family":"Rebolledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Getahun","family":"Abate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara M.","family":"Babu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine G.","family":"Rouphael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Wald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana M.","family":"El Sahly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Jooss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan G.","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mat","family":"Makowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjian","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Carmack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet I.","family":"Archer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamodikoe","family":"Makhene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Posavad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Juliana","family":"McElrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen C.","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhea","family":"Coler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Montefiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Eaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehul S.","family":"Suthar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Atmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"Hoft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128358_bb0005","unstructured":"World Health Organization. WHO COVID-19 Dashboard. https:\/\/data.who.int\/dashboards\/covid19\/cases?n=o and https:\/\/data.who.int\/dashboards\/covid19\/deaths?n=o. Accessed Feburary 8, 2025."},{"key":"10.1016\/j.vaccine.2026.128358_bb0010","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","article-title":"Global impact of the first year of COVID-19 vaccination: a mathematical modelling study","volume":"22","author":"Watson","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128358_bb0015","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/jama.2022.22759","article-title":"Urgent need for next-generation COVID-19 vaccines","volume":"329","author":"Marks","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2026.128358_bb0020","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"Gilbert","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2026.128358_bb0025","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/s41564-022-01262-1","article-title":"Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial","volume":"7","author":"Fong","year":"2022","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.vaccine.2026.128358_bb0030","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1146\/annurev-immunol-101721-061120","article-title":"T cell responses to SARS-CoV-2","volume":"41","author":"Sette","year":"2023","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.vaccine.2026.128358_bb0035","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41586-020-03041-6","article-title":"Correlates of protection against SARS-CoV-2 in rhesus macaques","volume":"590","author":"McMahan","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2026.128358_bb0040","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-27674-x","article-title":"Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts","volume":"13","author":"Kundu","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.128358_bb0045","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41586-021-04186-8","article-title":"Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2","volume":"601","author":"Swadling","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2026.128358_bb0050","doi-asserted-by":"crossref","unstructured":"Bange EM, Han NA, Wileyto P, Kim JY, Gouma S, Robinson J, et al. CD8(+) T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat Med 2021;27:1280\u20139.","DOI":"10.1038\/s41591-021-01386-7"},{"key":"10.1016\/j.vaccine.2026.128358_bb0055","doi-asserted-by":"crossref","unstructured":"Tan AT, Linster M, Tan CW, Le Bert N, Chia WN, Kunasegaran K, et al. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Rep 2021;34:108728.","DOI":"10.1016\/j.celrep.2021.108728"},{"key":"10.1016\/j.vaccine.2026.128358_bb0060","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","article-title":"The T cell immune response against SARS-CoV-2","volume":"23","author":"Moss","year":"2022","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2026.128358_bb0065","doi-asserted-by":"crossref","first-page":"14604","DOI":"10.1073\/pnas.1209367109","article-title":"Nonviral delivery of self-amplifying RNA vaccines","volume":"109","author":"Geall","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2026.128358_bb0070","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses","volume":"26","author":"Vogel","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2026.128358_bb0075","doi-asserted-by":"crossref","unstructured":"Oda Y, Kumagai Y, Kanai M, Iwama Y, Okura I, Minamida T, et al. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet Infect Dis 2024;24:351\u201360.","DOI":"10.1016\/S1473-3099(23)00650-3"},{"key":"10.1016\/j.vaccine.2026.128358_bb0080","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1473-3099(24)00060-4","article-title":"Persistence of immune responses of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2","volume":"24","author":"Oda","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128358_bb0085","doi-asserted-by":"crossref","unstructured":"Rappaport AR, Hong SJ, Scallan CD, Gitlin L, Akoopie A, Boucher GR, et al. Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infection. Nat Commun 2022;13:3289.","DOI":"10.1038\/s41467-022-31005-z"},{"key":"10.1016\/j.vaccine.2026.128358_bb0090","doi-asserted-by":"crossref","unstructured":"Low JG, de Alwis R, Chen S, Kalimuddin S, Leong YS, Mah TKL, et al. A phase I\/II randomized, double-blinded, placebo-controlled trial of a self-amplifying Covid-19 mRNA vaccine. NPJ Vaccines 2022;7:161.","DOI":"10.1038\/s41541-022-00590-x"},{"key":"10.1016\/j.vaccine.2026.128358_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101262","article-title":"Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial","volume":"44","author":"Pollock","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.vaccine.2026.128358_bb0100","doi-asserted-by":"crossref","unstructured":"Szubert AJ, Pollock KM, Cheeseman HM, Alagaratnam J, Bern H, Bird O, et al. COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2. EClinicalMedicine 2023;56:101823.","DOI":"10.1016\/j.eclinm.2022.101823"},{"key":"10.1016\/j.vaccine.2026.128358_bb0105","doi-asserted-by":"crossref","unstructured":"Palmer CD, Scallan CD, Kraemer Tardif LD, Kachura MA, Rappaport AR, Koralek DO, et al. GRT-R910: a self-amplifying mRNA SARS-CoV-2 vaccine boosts immunity for >\/=6 months in previously-vaccinated older adults. Nat Commun 2023;14:3274.","DOI":"10.1038\/s41467-023-39053-9"},{"key":"10.1016\/j.vaccine.2026.128358_bb0110","doi-asserted-by":"crossref","unstructured":"Akahata W, Sekida T, Nogimori T, Ode H, Tamura T, Kono K, et al. Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing an anchored RBD: a randomized, observer-blind phase 1 study. Cell Rep Med. 2023;4:101134.","DOI":"10.1016\/j.xcrm.2023.101134"},{"key":"10.1016\/j.vaccine.2026.128358_bb0115","doi-asserted-by":"crossref","unstructured":"Aboshi M, Matsuda K, Kawakami D, Kono K, Kazami Y, Sekida T, et al. Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine iScience 2024;27:108964.","DOI":"10.1016\/j.isci.2024.108964"},{"key":"10.1016\/j.vaccine.2026.128358_bb0120","doi-asserted-by":"crossref","unstructured":"Bulik-Sullivan B, Busby J, Palmer CD, Davis MJ, Murphy T, Clark A, et al. Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification. Nat Biotechnol 2018.","DOI":"10.1038\/nbt.4313"},{"key":"10.1016\/j.vaccine.2026.128358_bb0125","doi-asserted-by":"crossref","unstructured":"Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 2020;181:1489\u2013501 e15.","DOI":"10.1016\/j.cell.2020.05.015"},{"key":"10.1016\/j.vaccine.2026.128358_bb0130","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1126\/science.abd3871","article-title":"Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans","volume":"370","author":"Mateus","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2026.128358_bb0135","unstructured":"US Food and Drug Administration Center for Biologics Evaluation and Research. Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/toxicity-grading-scale-healthy-adult-and-adolescent-volunteers-enrolled-preventive-vaccine-clinical Accessed April 2, 2025.."},{"key":"10.1016\/j.vaccine.2026.128358_bb0140","doi-asserted-by":"crossref","unstructured":"Larsen SE, Berube BJ, Pecor T, Cross E, Brown BP, Williams BD, et al. Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples. J Immunol Methods 2021;499:113160.","DOI":"10.1016\/j.jim.2021.113160"},{"key":"10.1016\/j.vaccine.2026.128358_bb0145","doi-asserted-by":"crossref","unstructured":"Shen X, Tang H, McDanal C, Wagh K, Fischer W, Theiler J, et al. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Cell Host Microbe 2021;29:529\u201339 e3.","DOI":"10.1016\/j.chom.2021.03.002"},{"key":"10.1016\/j.vaccine.2026.128358_bb0150","doi-asserted-by":"crossref","unstructured":"Edara VV, Norwood C, Floyd K, Lai L, Davis-Gardner ME, Hudson WH, et al. Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. Cell Host Microbe 2021;29:516\u201321 e3.","DOI":"10.1016\/j.chom.2021.03.009"},{"key":"10.1016\/j.vaccine.2026.128358_bb0155","doi-asserted-by":"crossref","unstructured":"Edara VV, Pinsky BA, Suthar MS, Lai L, Davis-Gardner ME, Floyd K, et al. Infection and vaccine-induced neutralizing-antibody responses to the SARS-CoV-2 B.1.617 variants. N Engl J Med 2021;385:664\u20136.","DOI":"10.1056\/NEJMc2107799"},{"key":"10.1016\/j.vaccine.2026.128358_bb0160","doi-asserted-by":"crossref","unstructured":"Vanderheiden A, Edara VV, Floyd K, Kauffman RC, Mantus G, Anderson E, et al. Development of a rapid focus reduction neutralization test assay for measuring SARS-CoV-2 neutralizing antibodies. Curr Protoc Immunol 2020;131:e116.","DOI":"10.1002\/cpim.116"},{"key":"10.1016\/j.vaccine.2026.128358_bb0165","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1001\/jama.2021.4388","article-title":"Neutralizing antibodies against SARS-CoV-2 variants after infection and vaccination","volume":"325","author":"Edara","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2026.128358_bb0170","doi-asserted-by":"crossref","unstructured":"Xie X, Muruato A, Lokugamage KG, Narayanan K, Zhang X, Zou J, et al. An infectious cDNA clone of SARS-CoV-2. Cell Host Microbe 2020;27:841\u20138 e3.","DOI":"10.1016\/j.chom.2020.04.004"},{"key":"10.1016\/j.vaccine.2026.128358_bb0175","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/cyto.a.23753","article-title":"OMIP-056: evaluation of human conventional T cells, donor-unrestricted T cells, and NK cells including memory phenotype by intracellular cytokine staining","volume":"95","author":"Dintwe","year":"2019","journal-title":"Cytometry A"},{"key":"10.1016\/j.vaccine.2026.128358_bb0180","doi-asserted-by":"crossref","unstructured":"Cohen KW, Linderman SL, Moodie Z, Czartoski J, Lai L, Mantus G, et al. Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. Cell Rep Med 2021;2:100354.","DOI":"10.1016\/j.xcrm.2021.100354"},{"key":"10.1016\/j.vaccine.2026.128358_bb0185","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMoa2116414","article-title":"Homologous and heterologous Covid-19 booster vaccinations","volume":"386","author":"Atmar","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128358_bb0190","doi-asserted-by":"crossref","unstructured":"Koen A. Preliminary evidence of durable immune responses induced by self-amplifying mRNA (samRNA) vaccine candidates against SARS-CoV-2 in vaccine-naive South African population Open Forum Infect Dis 2023;10.","DOI":"10.1093\/ofid\/ofad500.1993"},{"key":"10.1016\/j.vaccine.2026.128358_bb0195","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.7326\/M22-1300","article-title":"Antinucleocapsid antibodies after SARS-CoV-2 infection in the blinded phase of the randomized, placebo-controlled mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"175","author":"Follmann","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2026.128358_bb0200","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S1473-3099(24)00565-6","article-title":"Immunogenicity of a booster dose of a bivalent (Asp614Gly and omicron BA.4\/5 variant) self-amplifying mRNA SARS-CoV-2 booster vaccine versus the BNT162b2 omicron BA.4\/5 mRNA vaccine: a randomised phase 3 trial","volume":"25","author":"Okada","year":"2025","journal-title":"Lancet Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26001660?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26001660?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T17:22:17Z","timestamp":1777569737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26001660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":40,"alternative-id":["S0264410X26001660"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128358","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The safety, reactogenicity, and immunogenicity of the self-amplifying mRNA COVID-19 vaccine GRT-R910 as a booster in healthy adults","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128358","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128358"}}